Nanobody Specialist Ablynx Bags Global IL-6R Deal With AbbVie
This article was originally published in The Pink Sheet Daily
Executive Summary
Ablynx stands to get $840 million and double-digit royalties under a global license deal with AbbVie to develop and commercialize the Belgian group’s anti-IL-6R candidate ALX-0061 to treat inflammatory diseases. The transaction brings a big boost to the biotech’s prospects.